SCHEMBL3279765

SCHEMBL3279765

O=C(O)c1ccccc1NS(=O)(=O)c1ccc(S)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.68
KDM4E B2RXH2 4/20 0.68
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
POLB P06746 1/20 0.65
HSD17B10 Q99714 4/20 0.59
LMNA P02545 1/20 0.59
GAA P10253 2/20 0.56
TP53 P04637 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SLC25A1 P53007 1/20 0.55
ACLY P53396 1/20 0.55
METAP2 P50579 1/20 0.55
CCR1 P32246 1/20 0.54
CCR2 P41597 1/20 0.54
HPGD P15428 2/20 0.54
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1466906 0.89 ALDH1A1 (0.72) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL16127963 0.86 ALDH1A1 (0.69) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL23879580 0.84 ALDH1A1 (0.68) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL15822907 0.84 ALDH1A1 (0.68) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL1688339 0.84 METAP2 (0.71) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL12200779 0.84 CCR2 (0.73) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL27770303 0.84 KDM4E (0.68) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL16088722 0.82 CA12 (0.66) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL12010883 0.81 BDKRB1 (0.67) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL15821426 0.81 SLC25A1 (0.65) ALDH1A1KDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152255-A1 Organic Compounds DAMON ROBERT EDSON 2010-06-17 US disclosed
US-7700637-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20070004704-A1 Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X NOVARTIS AG (CH) 2007-01-04 US disclosed
EP-1664002-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2006-06-07 EP disclosed
WO-2005026134-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152255-A1 Organic Compounds PPARG, FABP2, PPARA ALDH1A1 453/4885KDM4E 4091/4885MEN1 4132/4885
US-20070004704-A1 Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X PPARG, GPR119, PPARA ALDH1A1 845/4885KDM4E 1746/4885MEN1 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.